Q4 2021 Results

Participants Company overview Pharmaceuticals Oncology Financial review Conclusion Appendix Financial performance Innovation: Pipeline overview Innovation: Clinical trials CRM IHD Neuroscience Ophthalmology Respiratory & Allergy Oncology: Solid Tumors Hematology Biosimilars Global Health Abbreviations Cosentyx® - IL-17A inhibitor Study Indication Phase Patients Primary Outcome Measures Arms Intervention NCT03769168 (CAIN457F2304E1 - extension study) Psoriatic arthritis Phase 3 64 Number of participants with JIA ACR30 response Secukinumab 75 mg/0.5 ml Secukinumab 150 mg/1.0 ml Patients with juvenile idiopathic arthritis subtypes of juvenile psoriatic arthritis and enthesitis related arthritis Target Patients Read-out Milestone(s) 2025 Publication TBD NCT04156620 INVIGORATE-1 (CAIN457P12301) Axial spondyloarthritis Phase 3 500 The proportion of subjects achieving an ASAS40 (Assessment of SpondyloArthritis International Society criteria) response Secukinumab intravenous (i.v.) regimen Placebo intravenous (i.v.) regimen Patients with active axial spondyloarthritis Primary (week 16): 2022; Final: 2023 2023 81 Investor Relations | Q4 2021 Results NOVARTIS | Reimagining Medicine

View entire presentation